ACOR.Q Stock Overview
A biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Acorda Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.02 |
| 52 Week High | US$18.00 |
| 52 Week Low | US$0.013 |
| Beta | 1.69 |
| 1 Month Change | -84.62% |
| 3 Month Change | -96.88% |
| 1 Year Change | -99.88% |
| 3 Year Change | -99.97% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?
Feb 21
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement
Dec 18Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?
Jun 05Acorda wins $16.5M in Ampyra arbitration case with Alkermes
Oct 17Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on vote
Oct 10Acorda inks license deal with Asieris for pre-clinical drug
Aug 29Acorda Therapeutics announces resignation of COO
Aug 19Acorda Therapeutics: Managing The Transition
Oct 04Acorda Therapeutics Continues To Maneuver For A Turnaround
Jul 24CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action
Jun 17Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now
May 26Acorda Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts
Mar 09Shareholder Returns
| ACOR.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -28.5% | 1.8% | -0.8% |
| 1Y | -99.9% | -2.1% | 22.7% |
Return vs Industry: ACOR.Q underperformed the US Biotechs industry which returned 9.2% over the past year.
Return vs Market: ACOR.Q underperformed the US Market which returned 16.9% over the past year.
Price Volatility
| ACOR.Q volatility | |
|---|---|
| ACOR.Q Average Weekly Movement | 55.6% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ACOR.Q's share price has been volatile over the past 3 months.
Volatility Over Time: ACOR.Q's weekly volatility has increased from 34% to 56% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 102 | Ron Cohen | www.acorda.com |
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson’s disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.
Acorda Therapeutics, Inc. Fundamentals Summary
| ACOR.Q fundamental statistics | |
|---|---|
| Market cap | US$37.39k |
| Earnings (TTM) | -US$263.42m |
| Revenue (TTM) | US$115.66m |
0.0x
P/S Ratio0.0x
P/E RatioIs ACOR.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACOR.Q income statement (TTM) | |
|---|---|
| Revenue | US$115.66m |
| Cost of Revenue | US$20.48m |
| Gross Profit | US$95.19m |
| Other Expenses | US$358.61m |
| Earnings | -US$263.42m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -212.08 |
| Gross Margin | 82.30% |
| Net Profit Margin | -227.75% |
| Debt/Equity Ratio | -103.1% |
How did ACOR.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/13 21:49 |
| End of Day Share Price | 2024/08/13 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Acorda Therapeutics, Inc. is covered by 28 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert LeBoyer | Aegis Capital Corporation |
| Christopher Raymond | Baird |
| John Newman | Canaccord Genuity |